Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, has announced its participation in three upcoming investor conferences:

1. H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 4:00 p.m. ET in New York

2. Jefferies Global Healthcare Conference on June 5, 2025, at 9:55 a.m. ET in New York

3. Goldman Sachs Global Healthcare Conference on June 11, 2025, at 10:40 a.m. ET in Miami Beach

The company will conduct one-on-one meetings at all events. Live webcasts and 90-day archived recordings will be available on Phathom's investor relations website.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, along with associated inducement awards. The Board granted Bentley a non-qualified stock option to purchase 79,365 shares of common stock, with 25% vesting on May 1, 2026, and the remainder vesting in 36 monthly installments. Additionally, Bentley received 57,143 restricted stock units vesting in three equal annual installments and 50,000 restricted stock units vesting in two equal annual installments.

Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® for heartburn and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and DUAL PAK® for H. pylori infection treatment.

Phathom Pharmaceuticals reported Q1 2025 financial results and strategic changes. VOQUEZNA achieved over 390,000 prescriptions to date, with Q1 net revenues of $28.5 million. The company implemented cost reductions and leadership changes, including a 6% workforce reduction, aiming to cut 2025 operating expenses by $60-70M. New appointments include Jonathan Bentley as SVP of Sales and Ted Schroeder to the Board. Q1 saw 127,000 VOQUEZNA prescriptions filled, an 8% growth despite seasonal challenges. The company maintains strong commercial coverage for over 120M lives. Financial results show increased net loss of $94.3M compared to $82.9M in Q1 2024. Cash position stands at $212.3M, which management believes sufficient to achieve operational profitability by 2026.

Phathom Pharmaceuticals (Nasdaq: PHAT) will present real-world data for VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) in San Diego from May 3-6, 2025. The presentation includes two posters analyzing real-world treatment patterns and patient characteristics of VOQUEZNA-treated GERD patients.

VOQUEZNA is the first FDA-approved treatment of its kind for adults with Non-Erosive GERD and all severities of Erosive Esophagitis. The company will host a Product Theater and maintain booth #1743 at the conference.

Key events include:

• VOQUEZNA Product Theater on May 4, 2025 (12:15 PM PT)
• Independent Medscape CME Symposia on May 4 (6:00 PM PT)
• Real-world data poster presentations on May 5 (12:30 PM PT)

Phathom Pharmaceuticals (NASDAQ: PHAT) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 1, 2025, at 8:00 am EDT. The company will host a live webcast accessible through their investor relations website, with a recording available for 90 days afterward.

Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® (vonoprazan) tablets in the United States. Their product lineup includes treatments for:

• Non-Erosive GERD heartburn relief in adults
• Healing and maintenance of Erosive GERD in adults
• H. pylori infection treatment through VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®

Phathom Pharmaceuticals (PHAT) has appointed Ted Schroeder to its Board of Directors. Schroeder brings over 30 years of experience leading biopharmaceutical companies, with expertise in building commercial organizations, launching new therapies, and guiding companies through strategic milestones.

Board Chairman Michael Cola highlighted Schroeder's appointment comes at a pivotal period for Phathom, particularly as the company focuses on unlocking the full potential of VOQUEZNA®. Schroeder's operational and commercial expertise is expected to support Phathom's commercial momentum in delivering first-in-class therapies for gastrointestinal diseases.

Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, April 8th, 2025, at 10:15 am ET.

The conference, scheduled to run from April 7-10, 2025, will also feature one-on-one meetings with company management. A live webcast and archived recording of the event will be accessible through the Events & Presentations section of Phathom's website, with the recording remaining available for 90 days after the meeting.

Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of novel treatments for gastrointestinal (GI) diseases.

Phathom Pharmaceuticals (Nasdaq: PHAT) has announced the approval of inducement awards connected to Steven Basta's appointment as President and CEO. The compensation package includes:

• A non-qualified stock option to purchase 1,085,000 shares, with 25% vesting on April 1, 2026, and the remainder vesting in 36 monthly installments
• 360,000 performance stock units tied to stock price hurdles
• 180,000 performance stock units (with potential 200% target earnings) linked to revenue targets through December 31, 2027

The company, focused on gastrointestinal disease treatments, markets VOQUEZNA® tablets for heartburn and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment.

Phathom Pharmaceuticals (NASDAQ: PHAT) has announced a significant leadership change with the appointment of Steven Basta as President, CEO, and Board member, effective immediately. Basta replaces Terrie Curran, who is stepping down from her positions for personal reasons after five years of leadership.

The company, which focuses on developing and commercializing novel treatments for gastrointestinal (GI) diseases, views this transition as an opportunity to accelerate commercial growth. Chairman Michael Cola expressed confidence in Basta's extensive commercial expertise and track record in developing novel treatments.

Under this transition, Phathom aims to expand opportunities for their product VOQUEZNA® and enhance shareholder value. The new CEO emphasized his commitment to unlocking VOQUEZNA's full potential in addressing unmet needs in GI disease treatment.